Retinal Disease Clinical Trials

21 recruiting

Retinal Disease Trials at a Glance

27 actively recruiting trials for retinal disease are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Not Applicable with 6 trials, with the heaviest enrollment activity in Bethesda, Houston, and Ann Arbor. Lead sponsors running retinal disease studies include Duke University, National Eye Institute (NEI), and Optos, PLC.

Browse retinal disease trials by phase

Treatments under study

About Retinal Disease Clinical Trials

Looking for clinical trials for Retinal Disease? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinal Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinal Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

Retinal DiseaseGenotype
National Eye Institute (NEI)320 enrolled1 locationNCT01145196
Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting
Not Applicable

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease

Retinal Disease
University of Wisconsin, Madison50 enrolled1 locationNCT06380075
Recruiting

National Eye Institute Biorepository for Retinal Diseases

Age-Related Macular DegenerationDiabetic RetinopathyRetinal Disease+2 more
National Eye Institute (NEI)650 enrolled1 locationNCT01496625
Recruiting
Not Applicable

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

Retinal DiseaseGlaucomaOptic Nerve Diseases+1 more
Duke University50 enrolled1 locationNCT06841575
Recruiting
Not Applicable

Optimizing Low Vision Rehabilitation in Emotionally Distressed Patients With Inherited Retinal Diseases

Inherited Retinal Diseases
University of Michigan180 enrolled1 locationNCT06651736
Recruiting

Longitudinal Observational Study of Diabetic Retinopathy Progression in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2Diabetic RetinopathyDiabetic Complication+1 more
Association for Innovation and Biomedical Research on Light and Image100 enrolled1 locationNCT07458516
Recruiting

Data Gathering for A10900

HealthyRetinal DiseaseGlaucoma+1 more
Optos, PLC180 enrolled4 locationsNCT07149740
Recruiting
Phase 1Phase 2

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Phase 1Phase 2

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

Retinitis PigmentosaChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal Diseases
Kiora Pharmaceuticals, Inc.48 enrolled3 locationsNCT05282953
Recruiting

Intraoperative OCT Guidance of Intraocular Surgery II

Epiretinal MembraneHealthyStrabismus+7 more
Duke University262 enrolled1 locationNCT03713268
Recruiting

Optimize Pediatric OCT Imaging

Retinal DiseaseGlaucomaOptic Nerve Diseases
Duke University30 enrolled1 locationNCT06139523
Recruiting
Phase 3

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Retinal DegenerationMacular DegenerationDiabetic Retinopathy+3 more
Incepta Pharmaceuticals Ltd70 enrolled1 locationNCT06305416
Recruiting

Inherited Retinal Degenerative Disease Registry

Retinitis PigmentosaBatten DiseaseLeber Congenital Amaurosis+25 more
Foundation Fighting Blindness20,000 enrolled1 locationNCT02435940
Recruiting
Not Applicable

Stem Cell Ophthalmology Treatment Study II

Age-Related Macular DegenerationRetinitis PigmentosaMacular Degeneration+15 more
MD Stem Cells500 enrolled4 locationsNCT03011541
Recruiting
Phase 1

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

Retinal DegenerationRetinal DiseaseEye Diseases+2 more
PYC Therapeutics12 enrolled5 locationsNCT06455826
Recruiting
Not Applicable

A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Vitreoretinal Disease
Acusurgical15 enrolled1 locationNCT06294613
Recruiting
Early Phase 1

Safety and Efficacy Study of PUMCH-E101 Injection in Subjects with RDH12 Retinopathy

Inherited Retinal Diseases
Peking Union Medical College Hospital10 enrolled1 locationNCT06749639
Recruiting
Phase 1Phase 2

Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Geographic AtrophyAge-Related Macular DegenerationMacular Degeneration+2 more
Eyestem Research Pvt. Ltd.54 enrolled3 locationsNCT06394232
Recruiting
Phase 1Phase 2

Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)

Leber Congenital AmaurosisInherited Retinal Diseases Caused by RPE65 Mutations
HuidaGene Therapeutics Co., Ltd.20 enrolled3 locationsNCT05906953